TMED7-TICAM2 readthrough transcript (TMED7-TICAM2)

TMED7-TICAM2 readthrough transcript encodes a fusion protein produced by the naturally occurring read-through transcription between the TMED7 (Transmembrane emp24 domain-containing protein 7) and TICAM2 (TIR domain-containing adaptor molecule 2, also known as TRAM) genes[1][2][3]. Alternative splicing of this locus results in multiple transcript variants, of which this fusion protein incorporates domains from both gene products. The fusion protein negatively regulates the MyD88-independent Toll-like receptor 4 (TLR4) signaling pathway, acting as an inhibitor through facilitating the breakdown of the TRIF/TRAM complex and promoting TLR4 degradation[2][3]. TMED7-TICAM2 is primarily involved in innate immune responses by modulating TLR4 signaling after lipopolysaccharide (LPS) stimulation, contributing to precise regulation of downstream cytokine responses[2][3]. Although not a canonical receptor, enzyme, or well-characterized therapeutic target, it is biologically significant as a negative regulator in immune pathways. The fusion has been associated with various immune processes and possibly implicated in malignancies, but there is no established role as a direct drug target currently[2][3].

Other names

MyD88-4TICAM-2TICAM2TIRAP3TIRPTRAMTRAM adaptor with GOLD domainPutative NF-kappa-B-activating protein 502TIR domain-containing adapter molecule 2Toll-like receptor adaptor protein 3Toll/interleukin-1 receptor domain-containing proteinTMED7-TICAM2 read-through transcript